Anti-Human HLA-DRA Recombinant Antibody (1D09C3) (HM812107)

Name: Anti-Human HLA-DRA Recombinant Antibody (1D09C3)
Brand: abinScience
SKU: HM812107
Price: 118 USD
Availability: InStock

Fiche technique Partager le produit Copier les informations

Prix(USD) :

Spécification :

50ug
100ug

Nombre :

Contactez-nous

Aperçu
Images
Reférences
Fiche technique
SDS

Aperçu

Numéro de catalogue	HM812107
Reactivité des espèces	Human
Applications	FCM
Espèce hôte	Mouse
Clonalité	Monoclonal
Isotype	IgG1, kappa
ID de clone	1D09C3
Cible	HLA-DRA1, MHC class II antigen DRA, HLA-DRA, HLA class II histocompatibility antigen, DR alpha chain
Niveau d'endotoxines	Please contact with the lab for this information.
Pureté	>95% as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Numéro d'accès	P01903
Forme	Liquid
Tampon de stockage	0.01M PBS pH 7.4 Reférez-vous aux informations spécifiques sur le tampon dans la copie papier du datasheet ou dans le COA spécifique au lot.
Stabilité et stockage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Contexte	HLA class II histocompatibility antigen, DR alpha chain (HLA-DRA) is a ~28 kDa protein. An alpha chain of antigen-presenting major histocompatibility complex class II (MHCII) molecule. In complex with the beta chain HLA-DRB, displays antigenic peptides on professional antigen presenting cells (APCs) for recognition by alpha-beta T cell receptor (TCR) on HLA-DR-restricted CD4-positive T cells. This guides antigen-specific T-helper effector functions, both antibody-mediated immune response and macrophage activation, to ultimately eliminate the infectious agents and transformed cells. Typically presents extracellular peptide antigens of 10 to 30 amino acids that arise from proteolysis of endocytosed antigens in lysosomes. In the tumor microenvironment, presents antigenic peptides that are primarily generated in tumor-resident APCs likely via phagocytosis of apoptotic tumor cells or macropinocytosis of secreted tumor proteins. 1. Shams, H. et al. (2004) Journal of immunology (Baltimore, Md. : 1950) 173, 1966-77. PMID: 15265931 2. Röhn, TA. et al. (2004) Nature immunology 5, 909-18. PMID: 15322540 3. Deng, L. et al. (2007) Nature immunology 8, 398-408. PMID: 17334368 4. Kwok, WW. et al. (2012) Journal of immunology (Baltimore, Md. : 1950) 188, 2537-44. PMID: 22327072 5. Scally, SW. et al. (2013) The Journal of experimental medicine 210, 2569-82. PMID: 24190431 6. Muehling, LM. et al. (2016) Journal of immunology (Baltimore, Md. : 1950) 197, 3214-3224. PMID: 27591323 7. Galperin, M. et al. (2018) Science immunology 3. PMID: 29884618 8. Abelin, JG. et al. (2019) Immunity 51, 766-779.e17. PMID: 31495665 9. Stern, LJ. et al. (1994) Nature 368, 215-21. PMID: 8145819 10. Kropshofer, H. et al. (1997) Immunity 6, 293-302. PMID: 9075930
Note	For research use only.

Images

Bioactivity

SEC-HPLC detection for Anti-Human HLA-DRA Antibody (1D09C3).
Flow Cytometry

Flow-cytometry using anti-human HLA-DRA antibody. Human U-87 cell line were stained with an irrelevant antibody (Green Histogram) or an anti-human HLA-DRA antibody monoclonal antibody (Catalog # HM812107 , Red Histogram) at a concentration of 20 µg/ml for 30 mins at RT. After washing, bound antibody was detected using a CoraLite488 conjugated goat anti-mouse antibody (Catalog # MF690314) and cells analysed on a NovoCyte Flow Cytometer.